Epiminder
Epiminder is focused on transforming epilepsy management through its innovative Minder system, the first FDA-authorised implantable continuous EEG monitoring (iCEM) system. This technology provides continuous, long-term EEG monitoring, offering enhanced treatment planning and remote care capabilities for patients with drug-resistant epilepsy. Epiminder aims to improve the quality of life for epilepsy patients by providing actionable information regarding seizures and other EEG events.
Short position
Epiminder (ASX:EPI) has 0.01% of its shares on issue reported as short positions as of 21 Sept 2026, or about 19,014 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. EPI is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Epiminder (EPI) company profile
Profile, insiders and operations
Company
AI-generated research profile of Epiminder
EPI intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links